Last10K.com

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Aclaris Therapeutics, Inc.

CIK: 1557746 Ticker: ACRS

EXHIBIT 99.1

Aclaris New Logo

 

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2015 Operating and Financial Results 

 

Management to Host Conference Call at 4:30 p.m. ET today

 

Malvern, PA – March 23, 2016 (GLOBE NEWSWIRE) –

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2015 and provided an update on its clinical development programs. 

It has been an exciting time for Aclaris since our IPO in October of last year as we have made significant progress with the advancement of our development pipeline.  With our lead drug candidate, A-101, in the clinic for two indications (seborrheic keratosis and common warts), we look forward to seeing the results which we anticipate later this year.  We also continue to expand our pipeline by adding novel compounds to our clinical program such as our JAK (Janus Kinase) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions.  We continue to build a commercial infrastructure and have now assembled a senior management team with over 120 combined years of directly relevant experience in dermatology,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

Business Highlights and Recent Developments

 

·

Initiated Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis.  Earlier this year, the company initiated two Phase 3 clinical trials to evaluate A-101 Topical Solution for the treatment of seborrheic keratosis (SK).  The two Phase 3 clinical trials will evaluate the safety and efficacy of A-101 Topical Solution compared with a vehicle solution (placebo).  Approximately 800 subjects will be randomized in these multi-center, double-blinded, vehicle-controlled clinical trials, which are being conducted at 34 investigational centers within the United States.

 

·

Added to the Russell 2000® and Russell 3000® Indexes as part of Russell Investments' annual reconstitution effective as of December 21, 2015.

 

·

Appointed Brett Fair as Senior Vice President of Commercial Operations.    In December 2015, Mr. Fair joined Aclaris, bringing more than 18 years of pharmaceutical commercialization and business development experience.

 

·

Initiated Phase 2 Clinical Trial of A-101 for Treatment of Common Warts. In December 2015, the company initiated a Phase 2 clinical trial to evaluate A-101 Topical Solution for the treatment of common warts (verruca vulgaris).  This double-blinded, randomized Phase 2 trial, to be conducted at six sites in the United States, will evaluate the safety, tolerability and dose-response of two concentrations of A-101 compared with a vehicle control.  Aclaris intends to enroll approximately 108 subjects in this clinical trial.


The following information was filed by Aclaris Therapeutics, Inc. (ACRS) on Wednesday, March 23, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit)
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit) (parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Operations And Comprehensive Loss (parenthetical)
401(k) Savings Plan
401(k) Savings Plan (details)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Agreements Related To Intellectual Property
Agreements Related To Intellectual Property (details)
Commitments And Contingencies
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Convertible Preferred Stock
Convertible Preferred Stock (details)
Convertible Preferred Stock (tables)
Fair Value Of Financial Assets And Liabilities
Fair Value Of Financial Assets And Liabilities (detail)
Fair Value Of Financial Assets And Liabilities (tables)
Fair Value Of Financial Assets And Liabilities - By Type (details)
Income Taxes
Income Taxes (details)
Income Taxes (tables)
Net Loss Per Share
Net Loss Per Share (details)
Net Loss Per Share (tables)
Net Loss Per Share - Anti-dilution (details)
Organization And Nature Of Business
Organization And Nature Of Business (details)
Organization And Nature Of Business - Ipo, Stock Split, Liquidity (details)
Property And Equipment, Net
Property And Equipment, Net (details)
Property And Equipment, Net (tables)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (details)
Quarterly Financial Information (unaudited) (tables)
Related Party Transactions
Related Party Transactions (details)
Stock-based Awards
Stock-based Awards (details)
Stock-based Awards (tables)
Stock-based Awards - Compensation (details)
Stock-based Awards - Rsus (details)
Stockholders' Equity (deficit)
Stockholders' Equity (deficit) (tables)
Stockholders' Equity (deficit) - Common Stock (details)
Stockholders' Equity (deficit) - Restricted Stock (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)

Material Contracts, Statements, Certifications & more

Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ACRS
CIK: 1557746
Form Type: 10-K Annual Report
Accession Number: 0001558370-16-004311
Submitted to the SEC: Wed Mar 23 2016 5:01:37 PM EST
Accepted by the SEC: Wed Mar 23 2016
Period: Thursday, December 31, 2015
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-16-004311.htm